The test, which uses a anterior nasal swab sample, is “able to produce accurate, reliable and quick results in as few as 20 minutes” for SARS-CoV-2 and all variants of concern, including Omicron, the drug-maker said in a statement.
“Roche has the capacity to produce tens of millions of tests per month to help support the pandemic response,” the Swiss firm said, adding that the test will be available across the US from January. US President Joe Biden recently unveiled plans to buy 500 million rapid COVID-19 tests to be distributed for free to Americans who request them starting in January.